News | Amgen
WEBAMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024. 09.09.2024. AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024.
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
WEBOct 6, 2023 — Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
WEBAug 4, 2022 — Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease. Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology.
Press Releases - Amgen Inc.
WEBNEWS RELEASE 06.05.2024 AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
WEBMay 16, 2024 — IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response.
Newsroom - Amgen
WEBNewsroom. Amgen is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals.
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
WEBTHOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 ...
AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT …
WEBFeb 8, 2022 — Plans to Payout Approximately 60% of Non-GAAP Net Income on Average to Shareholders Through 2030. Broad and Diverse Portfolio of Innovative Brands and Biosimilars Positioned To Deliver Revenue Growth Over The Decade. Robust Mid- and Late-Stage Pipeline Positions the Company for Long-Term Growth.
Amgen | A Worldwide Pioneer in Biotechnology
WEBAmgen is a pioneer in the science of using living cells to make biologic medicines. READ MORE. Amgen’s medicines treat serious illnesses and typically address diseases with a …
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT …
WEBDec 1, 2022 — AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022. AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR. Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks. Initiating Phase 2 Study in Early 2023.